A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia

Recruiting

Phase 2

ML-007C-MAA Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia

Sponsor:

MapLight Therapeutics

Code:

NCT07038876

Conditions

Schizophrenia

Eligibility Criteria

Sex: All

Age: 18 - 64

Healthy Volunteers: Not accepted

Interventions

Placebo

ML-007C-MA BID

ML-007C-MA QD

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-02-22. This information was provided to ClinicalTrials.gov by MapLight Therapeutics on 2025-09-24.